Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Stock Spiked Tuesday

By George Budwell - Feb 21, 2018 at 8:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Agenus' steady march higher accelerated yesterday. Here's why.

What happened

Shares of the small-cap biotech Agenus (AGEN -1.58%) rose by as much as 11.2% yesterday on over four times the average daily volume. As a result, the stock is now up by a whopping 44% for the year.

What's going on? Investors appear to be warming up to the possibility that Agenus' broad pipeline of anti-cancer checkpoint inhibitors might be deeply undervalued. The company, after all, has licensing deals with both Incyte and Merck to develop checkpoint antibodies for a range of solid tumors. 

Man in a business suit pointing to an upward trending graph.

Image Source: Getty Images.

So what

Agenus stock has been one of the few big biotech winners in February so far -- even though the company hasn't released much in terms of news flow. This move higher seems to be backed by a solid change in sentiment toward the company's prospects at actually transforming into a leading immuno-oncology company.

Now what

The downside is that Agenus isn't expected to file for a regulatory approval for one of its checkpoint antibodies until 2019 at the earliest. That's particularly problematic because there are literally hundreds of similar therapies in development, at the moment.

Stated simply, Agenus may turn out to be developing nothing more than so-called "me-too" drugs with limited commercial upside potential. In that case, the biotech's present market cap of around $480 million is probably unwarranted. That's not to say that Agenus can't eventually strike gold with its checkpoint-inhibitor pipeline, but there's also the very real chance that the market will be saturated with competitors within the next two to three years.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
AGEN
$1.87 (-1.58%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.